Valrocemide

Valrocemide, also known as TV-1901, is an antiepileptic drug (AED) . Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy. (In Vivo) :In mice, valrocemide affords complete protection against maximal electroshock-, pentylenetetrazole-, picrotoxin-, and bicuculline-induced seizures and 6-Hz “psychomotor” seizures with median effective dose (ED50) values of 151, 132, 275, 248, and 237 mg/kg, respectively. Valrocemide is also effective in preventing sound-induced seizures in Frings audiogenic-seizure susceptible mice (ED50, 52 mg/kg) . The median neurotoxic dose in mice is 332 mg/kg. After oral administration to rats, valrocemide is active in the MES test, with an ED50 of 73 mg/kg, and the median neurotoxic dose is 1,000 mg/kg. Intraperitoneal administration of 300 mg/kg of valrocemide to hippocampal kindled Sprague–Dawley rats block generalized seizures and shorten the afterdischarge duration significantly. Valrocemide also provides complete protection from focal seizures in the corneally kindled rats (ED50, 161 mg/kg) .

92262-58-3

Valrocemide | TV-1901 | TV 1901 | TV1901 | SPD-493

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 499.30 mM

CCCC (CCC) C (=O) NCC (=O) N

C10H20N2O2

200.28

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.